POTSPOTS← HOME
TREATMENTS

Every POTS treatment, with the evidence behind it.

The list follows how guidelines build a plan: non-drug measures first, then medicines. Each card shows the best trial we could verify, how big it was, and what it could not show. Decisions about medicines belong to you and a doctor who knows your history.

HONEST STATE OF THE EVIDENCE
No medicine is approved by the FDA for POTS. A 2025 review of 21 randomized trials (750 patients) found many small trials and concluded that large trials are needed to know which drug should come first. Treat every benefit below as modest and short-term until bigger studies say otherwise. See also the treatment overview and recent research.
FIRST

Non-drug measures

Guidelines put these ahead of medicines. Most people use several together.

Extra fluids and salt

Drinking more water and eating more sodium aims to raise blood volume so the heart does not have to race to compensate.

GUIDELINE
HRS 2015: water 2 to 3 liters and 10 to 12 g of sodium chloride daily, Class IIb (weak recommendation, expert opinion level).
STATUS
Dietary measure. Ask your doctor first if you have high blood pressure, kidney or heart disease.
EVIDENCE
  • Garland 2021 · Randomized crossover, controlled diet, 6 days per arm, 14 with POTS, 13 controls
    A high-sodium diet lowered the heart rate rise on standing and raised plasma volume, yet the rise (46 bpm) stayed well above controls (19 bpm).
  • Medow 2019 · Physiologic crossover, single dose, 10 teens with POTS, 15 controls
    An hour after oral rehydration solution, tolerance to simulated standing rose from 100 to about 156 (IV saline: 135).
  • Snapper 2022 · Narrative review
    Concludes salt and water are the mainstay, while the published evidence of benefit is relatively weak.

LIMITSThe trials are tiny and short, and none tested the 10 to 12 g per day advice used in clinics over months. Symptom and long-term data are missing. A Calgary salt trial (NCT05924646) is recruiting.

Compression garments

Waist-high compression squeezes the abdomen and legs so less blood pools below the heart when you stand.

GUIDELINE
Named as first-line, non-drug care in the 2026 JAMA review.
STATUS
A garment, with no drug involved.
EVIDENCE
  • Bourne 2021 · Randomized crossover, 10-minute tilt, 30 adults with POTS
    Heart rate on tilt fell with more coverage: 109 bpm with none, 103 with leg garments, 97 abdominal, 92 full, with better symptom scores.
  • Bourne 2026 · Within-patient, garment on versus off, Small single-day study
    Abdominal garments lowered standing heart rate (103 versus 118 bpm) and symptom score. Effects reversed when removed.

LIMITSSingle-session effects only. No blinding is possible and no long-term outcome data exist. Comfort and heat limit wear for some people.

Reconditioning exercise

A graded program that starts lying down or seated (recumbent bike, rowing, swimming) and builds up over weeks to months.

GUIDELINE
HRS 2015: exercise, Class IIa (moderate recommendation, based on randomized evidence). JAMA 2026 describes structured supervised aerobic training as first line.
STATUS
Behavioral therapy.
EVIDENCE
  • Fu 2011 · Controlled trial, drug phase then exercise, 19 with POTS, 15 controls
    Three months of training lowered standing heart rate and raised physical functioning scores (33 to 50). Propranolol did not improve quality of life.
  • George 2016 · Uncontrolled registry of a community program, 251 enrolled, 103 completed
    Among completers, 71% no longer met POTS criteria and the rise fell from 46 to 23 bpm.
  • Cortez 2025 · Systematic review, no pooling, 7 studies
    Heart rate improved in all seven. Risk of bias was moderate to high in most.

LIMITSSmall studies, large dropout in the registry, and salt and water were part of the program, so exercise cannot be isolated. Many people feel worse before they feel better, so pace the ramp-up with a clinician.

THEN

Medicines (all off-label)

No drug has FDA approval for POTS. Doctors borrow medicines approved for other conditions and match them to your symptoms and blood pressure.

Low-dose propranolol (beta-blocker)

Slows the heart rate. Low doses worked better than high doses in the main trial.

GUIDELINE
HRS 2015: Class IIb.
STATUS
Off-label. Approved for hypertension, angina and other conditions; no approval covers POTS.
EVIDENCE
  • Raj 2009 · Randomized placebo-controlled crossover, single doses, 54 and 18
    20 mg lowered standing heart rate and improved symptoms at 2 hours. 80 mg lowered rate more but improved symptoms less.
  • Arnold 2013 · Randomized double-blind crossover, 11 with POTS
    20 mg raised exercise capacity (VO2max 24.5 to 27.6). 80 mg propranolol and metoprolol did not.
  • Moon 2018 · Randomized 2x2 trial, no placebo, 77 completers
    Propranolol, bisoprolol and each plus pyridostigmine all lowered symptom scores over 3 months. No placebo arm.

LIMITSHours-long endpoints, tiny samples, and no placebo in the 3-month trial. Can worsen asthma, low blood pressure and fatigue. Stopping suddenly is unsafe.

Pyridostigmine

Raises acetylcholine signaling, which slows heart rate on standing.

GUIDELINE
HRS 2015: Class IIb.
STATUS
Off-label. Approved for myasthenia gravis.
EVIDENCE
  • Raj 2005 · Randomized placebo-controlled crossover, single dose, 17
    30 mg lowered standing heart rate (100 versus 111 bpm) and improved symptoms at 2 hours.
  • Kanjwal 2011 · Retrospective chart review, 12-month follow-up, 203 treated
    43% of all treated, and 51% of those who tolerated it, improved. Gut side effects in 19%.

LIMITSHours-long and uncontrolled data only. About one in six could not tolerate it. Stomach cramps and diarrhea are common.

Midodrine

Tightens blood vessels so less blood pools in the legs.

GUIDELINE
HRS 2015: Class IIb.
STATUS
Off-label. Approved for symptomatic orthostatic hypotension, with a boxed warning for supine high blood pressure.
EVIDENCE
  • Kwok 2026 · Systematic review and meta-analysis, 14 studies, 968 patients
    Symptom benefit ranged from 46% to 91% across studies. Children had higher odds of response. The authors suggest second or third line use in adults.
  • Ross 2014 · Randomized double-blind crossover, 2 weeks, 20 teens and young adults
    Lowered upright heart rate in neuropathic POTS but not in hyperadrenergic POTS.

LIMITSMostly small or observational with high heterogeneity. Raises blood pressure when lying down. Goosebumps, scalp tingling and urinary retention occur.

Fludrocortisone

A salt-retaining steroid that expands blood volume.

GUIDELINE
HRS 2015: Class IIb (level C).
STATUS
Off-label. Approved for adrenal insufficiency.
EVIDENCE
  • Freitas 2000 · Open-label before and after, 11 women
    Symptoms improved after fludrocortisone, bisoprolol or both.

LIMITSNo randomized trial specific to POTS was found. Evidence is a small, old, uncontrolled report. Can lower potassium and raise blood pressure.

Ivabradine

Slows the sinus node directly without lowering blood pressure.

GUIDELINE
Discussed in the Canadian 2020 statement. Newer than the 2015 US consensus.
STATUS
Off-label. Approved for heart failure. Not for use in pregnancy.
EVIDENCE
  • Taub 2021 · Randomized double-blind crossover, 1 month each, 22 with hyperadrenergic POTS
    Lowered heart rate and improved physical and social functioning versus placebo, with no significant low heart rate or low blood pressure.
  • Kumar 2026 · Systematic review and meta-analysis, 9 studies, 245 patients
    Standing heart rate fell by 18.5 bpm on average. Side effects were mostly brief visual disturbances.
  • Kwok 2026 · Systematic review, 11 studies, 305 participants
    Every study showed a heart rate reduction. The authors rate the evidence low quality.

LIMITSOne small randomized trial in a single subtype. Everything else is observational. Slow heart rate, visual flashes and fainting can occur, and it needs contraception counseling.

Droxidopa and modafinil

Droxidopa raises norepinephrine. Modafinil promotes wakefulness and gets used for brain fog.

GUIDELINE
No guideline rating found.
STATUS
Off-label. Droxidopa is approved for neurogenic orthostatic hypotension. Modafinil is approved for narcolepsy, sleep apnea and shift work disorder.
EVIDENCE
  • Ruzieh 2017 · Retrospective, single center, 37 analyzed of 54
    Dizziness improved in about three quarters. Only 27% reported better quality of life and 40.5% stopped the drug.
  • Kpaeyeh 2014 · Randomized placebo-controlled crossover, single dose, 54
    Standing heart rate matched placebo, seated systolic pressure rose 5 mmHg, and symptoms were unchanged.

LIMITSNo randomized efficacy trial for droxidopa. The modafinil trial tested short-term safety only, not whether it helps thinking.

Intravenous saline

Fluid given by vein, used for acute flares in a medical setting.

GUIDELINE
HRS 2015: acute use for decompensation Class IIa. Regular infusions Class III (not recommended).
STATUS
Medical procedure.
EVIDENCE
  • HRS 2015 · Expert consensus statement
    Rates acute saline reasonable for a severe flare and advises against routine infusions.

LIMITSCentral lines used for repeated infusions carry infection and clot risks.

CAUTION

Medicines that can make it worse

Medicines that can worsen POTS

Norepinephrine reuptake blockers (some antidepressants and ADHD medicines) and stimulants can raise heart rate.

GUIDELINE
HRS 2015: drugs that block norepinephrine reuptake, Class III (harm).
STATUS
Check your own medicine list with a pharmacist or doctor.
EVIDENCE
  • HRS 2015 · Expert consensus statement
    Recommends against norepinephrine reuptake blockers in POTS.

LIMITSDo not stop a prescribed medicine on your own. Ask first.

STILL BEING TESTED

Investigational

Studied, and absent from guidelines so far.

IV immunoglobulin (IVIG) and other immune therapy

Tested because some POTS may involve autoimmunity.

GUIDELINE
Not recommended in any guideline.
STATUS
Investigational for POTS.
EVIDENCE
  • Vernino 2024 · Randomized controlled trial (iSTAND), 30 treated
    No difference from albumin: COMPASS-31 changed by -5.5 with IVIG and -10.6 with albumin.
  • argenx NCT05633407 · Phase 2 randomized, results on ClinicalTrials.gov, 53 with post-COVID POTS
    Efgartigimod did not beat placebo on COMPASS-31 at 24 weeks (-14.4 versus -16.0). The sponsor ended the extension study.
  • CSL Behring NCT06524739 · Phase 3, stopped early, 16 enrolled
    Too few participants for any efficacy conclusion.

LIMITSRegistry results are not peer reviewed. Small and short trials with presumptive autoimmune selection.

Ear (tragus) nerve stimulation

A device delivers mild electrical stimulation to the ear to shift autonomic balance.

GUIDELINE
Not in guidelines.
STATUS
Investigational for POTS.
EVIDENCE
  • Wang 2025 · Randomized sham-controlled, 57 with post-COVID POTS
    One month of stimulation lowered the heart rate rise on standing compared with sham, with effects reported at one year.

LIMITSSingle-region trial, small, and needs replication. The device is not widely available.

NOTE
This page summarizes published studies. It does not recommend a treatment for you. Dose, timing and safety depend on your blood pressure, other conditions, medicines and pregnancy plans. Never stop a prescribed medicine without asking the prescriber.

Want a record to bring to your visit? The POTS app guides the stand test at home and graphs your heart rate. See the app

© 2026 CORDOC LLCGuidesWalk-throughCheck numbersTreatmentsResearchVisit prepResourcesThe appPrivacyTerms